2027 ICD-10-CM Diagnosis Code E26.09Other primary hyperaldosteronism

ICD-10-CM Codes›E00–E89›E20-E35›E26

ICD-10-CM E26.09
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

E26.09 is a billable ICD-10-CM diagnosis code for other primary hyperaldosteronism. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 643 through 645. Coders also document this condition as familial hyperaldosteronism. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified endocrine disorders.

E26.09 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 23 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 23, ESRD (V21) category 23, ESRD (V24) category 23, and RxHCC Part D (V08) category 43 for payment year 2027.

Code Identity

ICD-10-CM Code
E26.09
Billable Status
Yes — Valid for Submission
Code Describes
Other primary hyperaldosteronism
Short Description
Other primary hyperaldosteronism
Same as the full description in the CMS dataset.
Parent Code
Primary hyperaldosteronism

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE20-E35Disorders of other endocrine glands
CategoryE26Hyperaldosteronism
This CodeE26.09Other primary hyperaldosteronism

Medicare Risk Adjustment (HCC)Billing

E26.09 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.

CMS-HCC V28 (Medicare Advantage Payment Model)
Not mapped
Dropped in V28 see all codes that no longer risk-adjust
Prior Model (CMS-HCC V24)
HCC 23
V24 retired last contributed to a Medicare Advantage risk score in payment year 2025
Other CMS Models
PACE (CMS-HCC V22): HCC 23 · ESRD (V21): HCC 23 · ESRD (V24): HCC 23
ESRD V21 weights: 0.013 dialysis, 0.234–0.359 functioning graft · ESRD V24 weights: 0.036 dialysis, 0.217–0.390 functioning graft
Part D (RxHCC)
RxHCC 43 — Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Familial hyperaldosteronism
  • Familial hyperaldosteronism type 4
  • Hyperaldosteronism co-occurrent with hyperplasia of the adrenal cortex
  • Idiopathic hyperaldosteronism
  • Primary aldosteronism
  • Primary hyperaldosteronism due to aldosterone-secreting malignant neoplasm of adrenal gland
  • Primary hyperaldosteronism due to hyperplasia
  • Primary hyperaldosteronism, seizures, neurological abnormalities syndrome

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to E26.09: its own notes plus those printed at block E20-E35 and Chapter 4. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • Primary aldosteronism due to adrenal hyperplasia (bilateral)

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From Block E20-E35 Disorders of other endocrine glands applies to 99 codes
From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Notes

General instructions on how these codes are used.

From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name E26.09, its category, or a range that includes it.

Code First 1

These codes say to code first a condition named in the note, and E26.09 is one of the conditions named.

  • G63 Polyneuropathy in diseases classified elsewhere
    endocrine disease, except diabetes (E00-E07, E15-E16, E20-E34) names E20-E34, which includes this code

Notes 1

These notes mention E26.09.

  • Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases
    All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere. names E16-E31, which includes this code

Index to Diseases and InjuriesGuidance

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END015
Other specified and unspecified endocrine disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Conn Syndrome

    primary hyperaldosteronism caused by the excess production of aldosterone by an adenoma of the zona glomerulosa or conn adenoma.

Patient EducationClinical

Adrenal Gland Disorders

Your adrenal glands are two small organs that sit on top of each kidney. The adrenal glands make different types of hormones you need to stay alive and healthy. Hormones are chemicals that travel in your bloodstream and control how different parts of your body work.

The full article covers:

  • What are adrenal glands?
  • What are adrenal gland disorders?
  • What causes adrenal gland disorders?
  • How are adrenal gland disorders diagnosed?
  • What are the treatments for adrenal gland disorders?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E26.09 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
255.10 Hyperaldosteronism NOS
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About E26.09Overview

What is the ICD-10 code for other primary hyperaldosteronism?

The ICD-10-CM code for other primary hyperaldosteronism is E26.09 (sometimes written as E2609). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is E26.09 (Primary hyperaldosteronism) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report other primary hyperaldosteronism on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does E26.09 group to?

When other primary hyperaldosteronism is the principal diagnosis on an inpatient stay, it groups to MS-DRG 644, 645, 643, with relative weights from 0.7461 to 1.6138 depending on complications. Higher weights mean higher Medicare reimbursement.

Can E26.09 be reported with N64.3?

Not as a rule. The Excludes1 note at block E20-E35, which applies to E26.09, lists "galactorrhea (N64.3)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What is the ICD-9 equivalent of E26.09?

Under the General Equivalence Mappings, other primary hyperaldosteronism converts to ICD-9-CM 255.10 (hyperaldosteronism NOS). The mapping is approximate, so confirm the match fits the documentation.

Does E26.09 risk-adjust for Medicare Advantage payment?

Not for Medicare Advantage. E26.09 mapped to HCC 23 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V21) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V24) category 23 (Other Significant Endocrine and Metabolic Disorders), and RxHCC Part D (V08) category 43 (Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders).